# Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed

> **NCT06102759** · — · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Adebrelimab，Fruquintinib

## Key facts

- **NCT ID:** NCT06102759
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2026-10-10
- **Final completion:** 2026-10-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06102759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06102759, "Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06102759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*